TLDR:
– Israeli venture studio AION Labs has announced a strategic partnership with early-stage VC firm Amiti Ventures.
– The partnership aims to advance healthcare towards more patient-centric precision medicine and bring new treatments to market.
AION Labs, a venture studio focused on using AI and computational science to solve therapeutic challenges, has partnered with early-stage VC firm Amiti Ventures. AION Labs builds and invests in startups focused on AI and biology in drug discovery and development, providing resources and mentorship. The partnership will contribute to advancing healthcare, making it more patient-centric and bringing new treatments to market.
The strategic partnership includes other companies such as AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, and Amazon Web Services (AWS), and is powered by BioMed X with the support of the Israeli Government through the Israel Innovation Authority.
Amiti Ventures brings complementary capabilities and expert investor knowledge to the AION Labs partnership, with its track record of identifying the best teams and investing early in innovative deep tech startups. This addition will enhance AION Labs’ expertise and capabilities in deep tech and computational technology domains, which are critical for the success of biotech innovation.
Amiti Ventures focuses on Seed-stage outlier companies that develop transformative technologies, particularly in quantum computing, computational biology, and synthetic biology.
Overall, this partnership between AION Labs and Amiti Ventures aims to tackle the challenges of drug discovery and development using computational bio approaches and entrepreneurial mindset. The venture studio model of AION Labs bridges the gap between academic research, generative AI advancements, and the development of new medicines, with the goal of revolutionizing healthcare.
